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Signatures of mutagenesis provide a powerful tool
for dissecting the role of somatic mutations in both
normal and pathological processes. Significantly,
cancer genomes are dominated by mutation signatures
distinct from those that accumulate in normal tissues
with age, with potentially important translational
implications.operative during the evolution of a tumor can be re-Deconvoluting mutational signatures in the
cancer genome
The initiation and progression of human cancers are
fueled by mutations and driven by adaptive selection.
Consequently, many of the heritable phenotypic changes
required to transform normal cells become etched in the
cancer genome. Advances in high-throughput sequen-
cing over the past decade have brought a greater appre-
ciation for the number and types of DNA alterations
that accumulate during cancer evolution. These somatic
alterations are typically classified as either “driver” muta-
tions, which confer selected cancer phenotypes, or the
far more numerous “passenger” mutations, which hitch-
hike with driver mutations but in and of themselves are
not thought to be directly selected. Both the multiplicity
and heterogeneity of these changes have unfortunately
confounded attempts to reduce the evolutionary com-
plexity of most cancers to a targetable number of recur-
ring driver mutations. Additionally, whether normal
mutation rates and processes are sufficient to explain
the mutation patterns found in cancer has been debated
for decades. In the last few years, DNA sequence ana-
lyses of cancer genomes have allowed the detection of
distinct mutational signatures and, more recently, those* Correspondence: eddiejfox@gmail.com
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for our understanding of cancer initiation, evolution,
and potentially for therapy.
Stratton and colleagues at the Sanger Center, among
others, have recently developed bioinformatic and com-
putational tools to deconvolute mutational signatures
that are over-represented in cancer genomes [1, 2].
Building on a large biochemical literature, they have
inferred that some of the distinct mutational processes
solved by analyses of the bases immediately 5′ and 3′ of
the mutated base [3]. Their initial studies show that
more than 20 mutational signatures, representing a
diversity of mutational processes underlying the develop-
ment of cancer, can be identified across multiple cancer
types.
Unlike cancer cells, normal cells replicate their ge-
nomes with extraordinary accuracy and have an arma-
mentarium of postreplicative DNA repair pathways to
ensure genetic stability. Neither DNA replication nor
postsynthetic DNA repair is, however, without error and
some of the more than 50,000 estimated DNA damage
events which occur daily within each normal cell can
result in mutation. The majority of these mutations, des-
tined to become passenger mutations should the result-
ing lineage ever be expanded, confer no demonstrable
phenotype. The catalog of mutations present in a cancer
genome at the time of sampling, therefore, is the sum of
“normal” mutational processes occurring from the time
an egg is fertilized and mutational processes occurring
in tumors from the time a cancer is initiated. Some
of these normal mutagenic processes will occur inter-
mittently, e.g., caused by exposure to environmental
mutagens, while others, such as replication errors,
would be predicted to generate mutations at a more
constant rate.
Now, using data from The International Cancer
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these analyses to deconvolute from cancer genomes the
signatures of mutations that likely occurred during nor-
mal aging from those that were acquired during malig-
nant transformation [4]. They identified two mutational
signatures, designated Signatures 1 and 5, for which the
number of attributable mutations was proportional to
the chronological age of the cancer patient at diagnosis.
Interestingly, both signatures exhibit different mutation
frequencies in different tissues and are not themselves
correlated; only three cancer types show an age-
correlation for both signatures (i.e., breast cancer, low-
grade glioma, and medulloblastoma). This is likely to
suggest that the underlying mechanisms of mutation are
different for each signature.
Signature 1 is largely made up of C>T substitutions at
CpG dinucleotides, which are likely caused by spontan-
eous deamination of 5-methylcytosine, enzymatic de-
amination of cytosine, or polymerase errors [5]. The
cancer types exhibiting high Signature 1 mutation fre-
quencies are chiefly derived from epithelia with high
turnover and the signature may well mark the number
of cell replications. Signature 5 primarily features a com-
bination of C>T and T>C transitions, exhibits a degree
of transcriptional strand bias, and may result from an
endogenously generated metabolite(s). In contrast to
Signature 1, the frequency of Signature 5, which also
displays substantial variation between cancer types, is
highest mainly in cancers of the brain, kidney, and
thyroid.
Mutation rates and cancer initiation
A striking finding of the studies is that no more than a
quarter of the mutations found in cancer genomes
exhibit any correlation with age or carry signatures of
the physiological mutagenic processes operative during
normal aging. Whether the mutation rate of cancer cells
is elevated relative to normal has been continuously
debated since the original description of the mutator
phenotype hypothesis [6]. Defects in pathways governing
genetic stability were reasoned to facilitate tumorigenesis
by fueling the reiterative process of mutation, selection,
and clonal expansion that drives cancer progression.
One of the earliest and most emphatic conclusions of
cancer genome sequencing studies was that, as predicted
by the mutator phenotype hypothesis, cancers carry vast
and varied numbers of mutations.
The quantification of the relative contribution of
physiological mutagenic processes to the cancer genome
now reinforces the concept that elevated rates of muta-
tion accumulation underpin the cancer phenotype. The
distinct mutational signatures of age-associated and
tumor-associated mutations also emphasize the funda-
mental differences between the mechanisms shapingnormal and cancer genomes. Importantly these findings
are also inconsistent with the proposal that the majority
of risk among different tissues to the development of tu-
mors can be explained by the number of normal stem
cell divisions in those tissues [7]. The large numbers of
mutations found in cancers was originally cited in
support of this; however, the lack of a common and
dominant age-related mutational signature argues
against random mutations arising during DNA repli-
cation in normal, non-cancerous stem cells as the
chief source of mutagenesis. The differences in age-
related mutational signatures between different tissues
must represent intrinsic differences in the lifetime ex-
posures to endogenously and exogenously generated
DNA damaging agents as well as differences in the
postsynthetic DNA repair and replicative capacities of
different cell types.
Implications for medicine
Aging is the greatest risk factor for malignancy. Modu-
lating the mutagenic processes underlying Signatures 1
and 5 could therefore offer the possibility of delaying
cancer initiation and other age-related pathologies. Add-
itionally, changes in mutation signatures might aid in
early cancer diagnosis or in the quantification of geno-
toxic exposures especially through the application of
“liquid” biopsies. The results of Alexandrov et al. suggest
that, in contrast to the prevailing focus of oncology on
blocking key signaling hubs in growth pathways of
tumor cells, mutation accumulation itself represents an
underappreciated therapeutic target. As high levels of
mutation are potentially deleterious, it has been pro-
posed that the mutation frequency of the cancer genome
is thresholded at a level below which cancers can
maximize their genetic diversity but still maintain fit-
ness, i.e., the population avoids undergoing an “error
catastrophe” [8]. In addition, while it is known that
prognosis and mutation load are correlated in both colo-
rectal and endometrial cancers, it is increasingly being
appreciated that a high neoantigen load, secondary to a
high mutation load, is also a major determinant of
response to immunomodulatory therapies in certain
cancers [9]. These observations have led to the proposal
that both the frequency and rate of mutation of cancer
cells, rather than individual driver mutations, might be
an effective target. Treatment of cancer cells with muta-
genic nucleoside analogs, for example, might result in
ablation of the tumor through induction of an immuno-
logically mediated error catastrophe [8].
Thus far, the identification of specific mutational sig-
natures attributable to specific biological processes is
largely correlative; of particular note, the age-correlated
signatures identified by Alexandrov et al. were obtained
from tumor genomes and not from histologically normal,
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model organisms are required before one can infer a
causal mechanism. It will be necessary, for example, to
modulate the rate-limiting step in specific biological path-
ways to determine if this results in alterations of the corre-
sponding mutational signature. Ultimately, the direct
investigation of in vivo somatic mutation rates and signa-
tures, for both tumor and normal tissue, will require
accurate sequencing of single cells and molecules [10].
Cancer is first and foremost a disease of DNA, where
evolutionary changes are driven by selection of stochas-
tically generated pre-existing variants. It has long been
argued that the rates and mechanisms of mutation op-
erative in normal cells cannot account for the large
numbers and types of mutations found in cancer and
that defects in pathways governing genetic stability must
be dysregulated to facilitate tumorigenesis. For the first
time, it has become possible to quantify mutational sig-
natures that likely occurred during normal aging relative
to those that were acquired during malignant transform-
ation and tumor progression. The capacity to accumu-
late mutations, rather than to mutate any particular
subset of genes, has once again been confirmed as one
of cancer’s key hallmarks.
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